一次情報の記録

重要申請提出

Metagenomi Announces FDA IND Clearance for MGX-001 in Hemophilia A

FDA cleared the IND for MGX-001, enabling initiation of the Phase 1/2 INTEGR8 trial. The company plans to start the trial in H1 2027 and report initial clinical data (safety, tolerability, FVIII activity) in H2 2027.

主要事実

提出
2026年11月10日 21:07
イベント
申請提出
方向
ポジティブ
アセット
MGX-001
出典
SEC 8-K
信頼度
出典あり

出典の抜粋

EX-99.1 2 mgx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A MGX-001 is designed to deliver durable, endogenous Factor VIII (FVIII) activity from a one-time treatment for adults and children Company plans to initiate the INTEGR8 clinical trial in the first half of 2027 and provide initial clinical data in the second half of 2027 $101.7 million in cash, cash equivalents, and available-for-sale marketable securities as of September 30, 2026, with runway anticipated to support operations into 2028 EMERYVILLE, Calif., November 10, 2026 (GLOBE

SEC 8-K

このアセットの詳細

2026年3月5日
21:09
MGXMetagenomi

Metagenomi、MGX-001のpre-INDミーティングを完了;IND申請は2026年4Q予定

試験登録の変更SEC 8-K
Metagenomi Announces FDA IND Clearance for MGX-001 in Hemophilia A | SimianX AI